Plain-English translation of NCT07086469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called surufatinib combined with chemotherapy and immunotherapy drugs (paclitaxel, cisplatin, and toripalimab) along with radiation therapy. The goal is to see if this combination can help patients with advanced esophageal squamous cell carcinoma—a type of esophageal cancer that has grown too large to be removed by surgery. Researchers want to know if adding this medication makes the treatment more effective and safe.
Esophageal cancer is a serious disease, and many patients cannot have surgery because their cancer is too advanced. This trial is exploring whether this medication, when combined with existing chemotherapy and radiation treatments, can improve outcomes for these patients and help them live longer.
You likely qualify if…
You likely don't qualify if…
You would first receive two cycles of chemotherapy combined with the new medication and an immunotherapy drug over several weeks. After that, you would undergo radiation therapy to your esophagus while continuing to take some of the same medications. Throughout the trial, you will have regular visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and watch for any side effects. The entire treatment period will take several weeks to months.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China